-The Hindu Business Line Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent. The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint...

More »